del Pozo E, Goldstein M, Friesen H, Brun del Re R, Eppenberger U
Am J Obstet Gynecol. 1975 Dec 1;123(7):719-23. doi: 10.1016/0002-9378(75)90494-9.
Bromocriptin (CB 154) has been found to suppress established lactation at a time when human plasma prolactin (HPRL) concentrations have already returned to the nonpregnant range. This action is due to inhibition of prolactin from the pituitary. It was then thought that a similar degree of inhibition induced during the menstrual cycle may help to uncover other possible biological actions of prolactin. In an attempt to elucidate this question eight breast-feeding mothers and seven normally menstruating volunteers underwent treatment with CB 154, including blood sampling during a sleep period. The dosage was 1 mg., three times daily, for 14 days in the first group and for a whole cycle in the normal volunteers. A control cycle preceded drug administration in the latter group. Prolactin (HPRL), growth hormone (HGH), luteotropin (LH), progesterone (PG), and estradiol (E2) were estimated (mean +/- standard error) along the menstrual cycles in the normal volunteers. HPRL and milk volumes were measured in the breast-feeding women in the base-line period and during treatment. In the postpartum group, basal HPRL had already reached normal levels prior to therapy (10.8 +/- 1.0 ng. per milliliter) and was significantly (p less than 0.002) depressed to 3.7 +/- 0.4 ng. per milliliter by CB 154. This degree of inhibition was effective in suppressing lactation within 24 to 48 hours in all of the subjects in that group. The fall in plasma HPRL from 9.5 +/- 1.5 ng. per milliliter to 3.2 +/- 0.2 ng. per milliliter observed in the normally menstruating women was similar to the one recorded in the breast-feeding group, but the sequence of hormonal changes during the menstrual cycle was not altered by treatment. The overnight study ensured around-the-clock prolactin inhibition. Results indicate no action of prolactin in the regulation of the human menstrual cycle at levels of inhibition at which a biological action of this hormone is clearly suppressed.
已发现溴隐亭(CB 154)在人血浆催乳素(HPRL)浓度已恢复到非孕期范围时,仍能抑制已建立的泌乳。此作用归因于对垂体催乳素的抑制。当时认为,在月经周期中诱导出类似程度的抑制可能有助于揭示催乳素的其他潜在生物学作用。为阐明这一问题,8名哺乳期母亲和7名正常月经的志愿者接受了CB 154治疗,包括在睡眠期间进行采血。第一组的剂量为每日3次,每次1毫克,共14天;正常志愿者则服用一整个周期。后一组在给药前有一个对照周期。对正常志愿者在整个月经周期中估算了催乳素(HPRL)、生长激素(HGH)、促黄体素(LH)、孕酮(PG)和雌二醇(E2)(均值±标准误差)。在基线期和治疗期间测量了哺乳期妇女的HPRL和奶量。在产后组中,治疗前基础HPRL已达到正常水平(每毫升10.8±1.0纳克),经CB 154治疗后显著降低(p<0.002)至每毫升3.7±0.4纳克。这种抑制程度在该组所有受试者中均能在24至48小时内有效抑制泌乳。正常月经妇女中观察到的血浆HPRL从每毫升9.5±1.5纳克降至每毫升3.2±0.2纳克,与哺乳期组所记录的情况相似,但月经周期中激素变化的顺序未因治疗而改变。夜间研究确保了催乳素的全天候抑制。结果表明,在该激素的生物学作用被明显抑制的抑制水平下,催乳素对人类月经周期的调节无作用。